SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc., an oncology precision medicine biotechnology company, today announced the pricing of an underwritten public offering of 5,245,000 shares of its common stock at a public offering price of $9.15 per share, resulting in gross proceeds of approximately $48.0 million. In connection with the offering, shares of Ignyta common stock will commence trading on the NASDAQ Capital Market under the ticker symbol “RXDX” on March 14, 2014. In addition, Ignyta has granted the underwriters a 30-day option to purchase up to an additional 786,750 shares of common stock.
Help employers find you! Check out all the jobs and post your resume.
